Denosumab and zoledronic acid therapy improves BMD in periprosthetic bone
Written By : Jacinthlyn Sylvia
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-06-20 04:00 GMT | Update On 2023-06-20 07:03 GMT
Advertisement
A new study by Xiao Li and team showed that denosumab and zoledronic acid (ZA) are effective treatments against decline in periprosthetic bone mineral density. The findings of this study were published in Archives of Osteoporosis.
Following a total hip arthroplasty (THA), periprosthetic bone mineral density (BMD) loss may endanger the longevity of implants. By suppressing osteoclast activity, zoledronic acid and denosumab were successful in lowering bone loss in diseases linked to rapid bone turnover. In order to evaluate the effectiveness and safety of ZA and denosumab for periprosthetic BMD loss following THA, a meta-analysis was conducted.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.